Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)

NCT00777296 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: ARIKACE™
DRUG: Placebo

Sponsor

Insmed Incorporated